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Abstract
Men with prostate cancer face difficult choices when selecting a therapy for localized prostate 
cancer. Comparative data from controlled studies are lacking and clinical opinions diverge about 
the benefits and harms of treatment options. Consequently, there is limited guidance for patients 
regarding the impact of treatment decisions on quality of life. There are opportunities for public 
health to intervene at several decision-making points. Information on typical quality of life 
outcomes associated with specific prostate cancer treatments could help patients select treatment 
options. From 2003 to present, the Division of Cancer Prevention and Control at CDC has 
supported projects to explore patient information-seeking behavior post-diagnosis, caregiver and 
provider involvement in treatment decision making, and patient quality of life following prostate 
cancer treatment. CDC's work also includes research that explores barriers and facilitators to the 
presentation of active surveillance as a viable treatment option and promotes equal access to 
information for men and their caregivers. This article provides an overview of the literature and 
considerations that initiated establishing a prospective public health research agenda around 
treatment decision making. Insights gathered from CDC-supported studies are poised to enhance 
understanding of the process of shared decision making and the influence of patient, caregiver, 
and provider preferences on the selection of treatment choices. These findings provide guidance 
about attributes that maximize patient experiences in survivorship, including optimal quality of 
life and patient and caregiver satisfaction with information, treatment decisions, and subsequent 
care.
Introduction
More than 200,000 men are diagnosed with prostate cancer annually,1 the majority 
diagnosed with localized disease.2,3 Treatment choices available to newly diagnosed, early-
stage prostate cancer patients include radical prostatectomy; brachy-therapy; external beam 
radiation; and active surveillance (AS).3 Most of these treatments can affect health-related 
quality of life (QOL)3 as a result of significant morbidity and physical side effects. 
However, AS may be associated with increased anxiety, missed opportunity for cure, risk of 
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progression or metastasis, more complex subsequent treatment, frequent medical exams, and 
periodic biopsies that may result in complications.4
Given the number of choices available for active treatment and their potential side effects, 
new patients may experience difficulty deciding what treatment is best suited for their 
cancer, personal preferences and health status, and home support environment, and 
information on typical QOL outcomes associated with prostate cancer treatments could 
guide patients in selecting treatment options. For many men, treatment discussions and 
decisions may take place at home with family.5 Treatment choices are inevitably influenced 
by three decision makers: the patient; the physician; and (when present) the patient's family 
(e.g., spouse/partner or caregiver).6 In 2003, there were no known published prospective 
studies that examined the influence of this triad of decision makers on treatment decisions or 
prospectively explored how knowledge, preferences, and interactions among prostate cancer 
patients, caregivers, and treating physicians ultimately influence treatment choice, QOL, and 
treatment satisfaction.
In 2003, CDC supported two Prevention Research Centers (University of Washington and 
Emory University) to prospectively examine men's selection of prostate treatment, caregiver 
involvement, and patient, caregiver, and physician perceptions of patient QOL. These 
studies focused on information-seeking behavior, how treatment decisions are made, and 
patient-reported QOL 12 months following diagnosis. Manuscripts from these studies, 
published in 2006–2013, document the importance of patient characteristics in evaluating 
patient QOL7 and treatment decision making,8,9 factors that influence treatment decisions,10 
and the impact of race and residence on these decisions.9 Other studies elucidated patient 
experiences with second opinions,11 QOL at 12 months of follow-up,12 use of 
complementary and alternative medicine,13 and racial differences in treatment-based beliefs 
and coping.14 Additional studies explored physician–caregiver interactions15 and caregiver 
roles16 in the decision process, as well as caregiver burden.17–19 Studies also examined the 
process of building a collaborative study team20 and the agreement of data ascertained from 
multiple sources.21
The predominant finding was that men diagnosed with low-grade tumors, who would likely 
die from other causes before disease progression, almost always opted for active treatment 
regimens. Many of the men who chose curative treatment were likely candidates for an AS 
protocol where low-risk prostate cancer is closely monitored but not treated immediately. 
AS allows men to avoid the potential side effects of radiation and surgery (e.g., urinary 
incontinence, impotence), reduces risk of treatment of small indolent cancers, and has 
minimal effect on QOL.22 Patients may opt for active treatment at any time, or physicians 
can intervene if the tumor profile worsens. Data showed that 79% of men considering AS 
reported a physician recommendation.9 These findings highlighted the need for further 
examination of factors associated with recommending, accepting, and participating in an AS 
protocol. This article reviews CDC-supported work in prostate cancer and describes the 
evolution of its research agenda.
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Focus on Active Surveillance
State of the Science Conference
In 2009, building on findings from QOL research, CDC initiated discussions with the Office 
of Medical Applications Research, NIH, and the National Cancer Institute to discuss interest 
in convening a State of the Science (SOS) conference to assess the availability of published 
evidence to distinguish patients who may be good candidates for AS. Subsequently, the 
Office of Medical Applications Research entered into partnership with CDC, the National 
Cancer Institute, and the American Cancer Society to outline an agenda for the conference. 
Through review of the literature,23 clinical profiles, and tumor and behavioral characteristics 
presented by leaders in the field, the conference panel was charged with synthesizing the 
state of current knowledge, identifying gaps in knowledge, and articulating a research 
agenda.
The NIH SOS Conference: Role of Active Surveillance in the Management of Men with 
Localized Prostate Cancer was held December 2011. A monograph of conference 
proceedings24 summarized all evidence presented at the conference along with a reprint of 
the panel consensus statement. The panel concluded that there was not sufficient evidence to 
allow definitive determination of the optimal characteristics of prime AS candidates, but that 
research needs be conducted to allow physicians and researchers to identify men 
appropriately.25 Such an AS research agenda needs to
1. determine which men are the most appropriate candidates;
2. determine what is the optimal protocol for surveillance;
3. determine how to best communicate AS as an option to patients;
4. develop methods to assist patient decision making;
5. clarify patient reasons for accepting or rejecting AS as a treatment strategy; and
6. conduct multicenter studies that incorporate community settings and partners.
The SOS conference concluded that AS be offered more frequently to more patients with 
low-risk prostate cancer.25 These recommendations can be used to generate discussion 
among physicians about greater use of AS among patients with low-risk tumor profiles, 
foster research that assists in better characterizing optimal candidates for AS, and assist in 
the development of decision aids that present AS with similar weight and detail as active 
treatments.
Assessment of Patient Perceptions of Active Surveillance
Testimony presented during the SOS conference highlighted qualitative research that 
compared AS, surgery, and radiation therapy.26 Results showed that information about 
treatment options can be presented such that men accepted AS as an option in relation to the 
major treatments26; however, no literature specifically asked patients and caregivers what 
types of information their physicians needed to provide to make AS an equally viable option 
to active treatment.
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In 2009, concomitant with SOS planning talks, CDC funded two Prevention Research 
Centers (University of Texas Health Science Center at Houston and Emory University) to 
determine, from the patient and caregiver perspective, desired talking points and preferred 
content about AS. These studies could provide the basis for developing an educational 
intervention for physician discussion with patients about AS and the preferred patient 
content to include in conversations that would aid in making AS an acceptable alternative.
Study 1: Acceptability of Active Surveillance as a Treatment Choice for Prostate Cancer 
Among U.S. Men
The University of Texas Health Science Center at Houston assembled convenience samples 
of African American, Hispanic, and non-Hispanic white men recruited from Houston and El 
Paso, aged 40–70 years, who had a prostate-specific antigen test within the previous 2 years, 
and no history of prostate cancer.27 Men and identified caregivers participated in a series of 
focus groups segmented by gender; race/ethnicity; and language (English, Spanish), 
conducted between May 2010 and February 2011. Groups discussed how participants would 
make treatment decisions if they (or their partners) were diagnosed with early-stage 
localized prostate cancer, what information would be needed to make an informed decision, 
how they would evaluate information, and who they would involve in the decision-making 
process.27 Additionally, following a separate recruitment of newly diagnosed patients, 15 
men who selected AS and 15 men treated with surgery or radiation participated in telephone 
interviews about discussed and considered treatment options, patient descriptions of AS, 
how the decision was made, physician recommendations, and their partner's role in decision 
making.28
Study 2: Active Surveillance Attitudes and Perceptions: Decision Making by Men and Their 
Significant Others for Early-Stage Prostate Cancer
Emory University's AS Attitudes and Perceptions study, conducted from September 2009 
through September 2012, utilized a multicenter, mixed-methods design, combining both 
qualitative and quantitative methodologies to assess factors men and their caregivers regard 
as vital to informed decision making about prostate cancer therapies. Separate patient 
(n=214) and caregiver (n=188) focus groups were held across six locations.29
Results from the above studies suggested that information about the nature of prostate 
cancer, available options, the benefits and harms of the options, and their likelihood of 
occurrence should be included in decision aids to assist patients in their discussions with 
providers and expressing their outcome preferences. Decision aids should also offer prompts 
for questions to doctors and messages designed to reinforce the importance of sharing one's 
preferences.27 Men who made treatment decisions displayed receptiveness to AS when fully 
informed about this option,28 and described it as an organized process with a rigorous and 
reassuring protocol of periodic testing, with potential for subsequent and timely decision 
making about any future treatment, and as an option for prolonging good health and 
function. Rationales for choosing AS included “buying time” without experiencing adverse 
effects of treatment, waiting for better treatments, trusting their physician's monitoring, and 
perceiving their cancer as very low risk.28 The AS Attitudes and Perceptions study revealed 
that men were more concerned about treatment side effects whereas caregivers were more 
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interested in a treatment's potential to increase survival and preferred that primary care 
providers (versus urologists or radiologists) should discuss all prostate cancer options with 
patients (particularly AS), as primary care providers were perceived as neutral advocates for 
patients.30
Lessons Learned
CDC-supported work revealed that the majority of men newly diagnosed with prostate 
cancer opt for surgery or radiation. The SOS conference panel recommended that AS be 
offered to more men. Information was needed to help patients and caregivers in their 
consideration of AS. The conference garnered insights into how to initiate discussions with 
patients about AS and elicited patient and caregiver concerns regarding AS and other 
treatment choices. Patients taught that being well informed about AS facilitates acceptability 
and that some men prefer to have such discussions with primary care physicians.
Putting It Together
Future CDC research may include investigations about the various components of the AS 
conversations, methods to support patient treatment decision making, and ensuring that all 
patients are informed and educated about all of their treatment options. Additional studies 
may explore barriers and facilitators of AS as a viable treatment option and ensure that it is 
presented to appropriate patients with the same emphasis as active treatments. Consistent 
with the SOS agenda to develop methods to assist patient decision making, CDC sought to 
explore the design of a treatment decision aid with a substantial AS component that would 
acknowledge sociodemographic and cultural differences, attend to patient informational 
needs and consider patient desired goals and outcomes, facilitate collaborative involvement 
of both the patient and caregiver in the decision process, and address the role of the 
provider. AS is frequently given little attention in decision aids, and an effective decision aid 
could provide more-complete and accurate descriptions of this option and represent it as an 
appropriate strategy for men with low-risk localized prostate cancer who are concerned 
about aggressive treatment complications.31 Decision aids should also meet quality 
standards for content, development processes, and effectiveness—demonstrating their ability 
to increase knowledge about treatment options and improve harmony between patient values 
and the selected treatment.32
Study 1: Development and Evaluation of an Interactive Clinical Decision Dashboard to 
Support Treatment Decisions for Men With Low-Grade, Local-Stage Prostate Cancer
In 2014, CDC funded the University of Rochester to develop and test an interactive 
multimedia decision aid in the form of a clinical decision dashboard,33 designed to improve 
the quality of clinical decision making for initial treatment of patients with newly diagnosed, 
low-risk prostate cancer. The tool will be designed to allow for multiple considerations 
(tumor characteristic, patient preferences, caregiver input) during decision-making 
deliberations with the goals of
1. informing recently diagnosed men of their treatment options, including AS, and 
helping them to determine their treatment preferences; and
Hall and Smith Page 5
Am J Prev Med. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2. supporting providers by providing up-to-date information summaries about 
treatment outcomes tailored for individual patient demographics and tumor 
characteristics.
A clinical trial will be conducted to compare the effects of the prostate decision dashboard 
versus usual care on patient knowledge regarding the management and treatment options 
available, measures of the decision-making process including decisional conflict and shared 
decision-making process, the selected treatments, and 6- and 12-month outcome assessments 
of clinical status, decisional regret, and cancer-related QOL.
Impact of CDC Research Agenda
Since 2003, CDC has engaged in a prostate cancer public health research agenda that has 
informed understanding of the needs and experiences of survivors of localized prostate 
cancer. This research has identified the following priorities for public health:
1. engaging in education to effectively inform patients and caregivers about the 
various available treatments and support the decision-making process, particularly 
among men who are traditionally medically underserved;
2. providing decision tools for patients, caregivers, and providers to promote effective 
conversation about all treatment options, including AS;
3. engaging in regular surveillance and evaluation of AS uptake, including 
sociodemographic, QOL, and clinical measures;
4. reducing loss to follow-up of men on AS protocols; and
5. tracking and evaluating decisions to terminate an AS protocol, including clinical 
status and QOL outcomes pre– and post–active treatment.
In the 4 years since the SOS conference, use of AS for patient management has grown in 
popularity,34,35 and research has proliferated in a number of areas, including better 
characterization of suitable AS candidates,36,37 defining appropriate standardized AS 
protocols,38 risks associated with monitoring,39 and criteria for disease progression.40 
Recent studies have reviewed the quality of care received by patients undergoing AS,41 and 
new tools to safely monitor low-risk prostate cancer42,43 are being proposed, such as use of 
biomarkers to better stratify risk of disease progression.44–46 New studies are beginning to 
quantify the number of men who are lost to follow-up while on AS protocols.47 Overall 
knowledge of who needs to be offered AS and how to monitor them has improved.
Future research may more explicitly characterize an appropriate AS protocol for African 
American men. Recent literature suggests that the tumors of African American men on AS 
initially characterized as low risk are often upgraded on serial biopsy,48 have worse 
pathologic characteristics,49 and that disease is more likely to recur following surgery50 
compared with men of other races, although these results have not been confirmed in other 
studies.51 These findings have raised the question of whether AS is appropriate for African 
American men, if this group requires more-stringent surveillance strategies, or whether more 
extensive initial clinical indicators to determine eligibility for AS are warranted. Methods to 
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effectively determine the potential aggressiveness of small tumors and the exact protocols 
for monitoring all men are needed.
CDC's early prostate cancer work highlighted that poor physician communication was 
associated with men not making a treatment choice, especially among African American 
men.9 Education about active treatments, AS, potential for complications and recurrence, 
physical side effects, and impact on QOL is still needed by all decision makers to inform 
choices made by men and their caregivers.52 CDC-funded work has served as a model for 
assessing the perspectives of patient, caregiver, and physician, promoting discussion of AS, 
and developing tools to assist patient–physician conversations. Improving the quality of 
survivorship among men diagnosed with localized prostate cancer will include identifying 
the correct patients for certain treatments, improving patient knowledge and awareness 
about treatment choices, and understanding the impact and roles of providers and caregivers 
in treatment decision making. CDC and its partners remain committed to exploring aspects 
of prostate cancer treatment decision making that present opportunities to improve cancer 
survivorship, reduce overtreatment, and enhance QOL of patients and caregivers.
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